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Abstract
Introduction Information on the metastasis process in breast
cancer patients undergoing primary tumour removal may be
extracted from an analysis of the timing of clinical recurrence.
Methods The hazard rate for local-regional and/or distant
recurrence as the first event during the first 4 years after surgery
was studied in 1173 patients undergoing mastectomy alone as
primary treatment for operable breast cancer. Subset analyses
were performed according to tumour size, axillary nodal status
and menopausal status.
Results A sharp two-peaked hazard function was observed for
node-positive pre-menopausal patients, whereas results from
node-positive post-menopausal women always displayed a
single broad peak. The first narrow peak among pre-menopausal
women showed a very steep rise to a maximum about 8–10
months after mastectomy. The second peak was considerably
broader, reaching its maximum at 28–30 months. Post-
menopausal patients displayed a wide, nearly symmetrical peak
with maximum risk at about 18–20 months. Peaks displayed
increasing height with increasing axillary lymph node
involvement. No multi-peaked pattern was evident for either pre-
menopausal or post-menopausal node-negative patients;
however, this finding should be considered cautiously because
of the limited number of events. Tumour size influenced
recurrence risk but not its timing. Findings resulting from the
different subsets of patients were remarkably coherent and each
observed peak maintained the same position on the time axis in
all analysed subsets.
Conclusions The risk of early recurrence for node positive
patients is dependent on menopausal status. The amount of
axillary nodal involvement and the tumour size modulate the risk
value at any given time. For pre-menopausal node-positive
patients, the abrupt increase of the first narrow peak of the
recurrence risk suggests a triggering event that synchronises
early risk. We suggest that this event is the surgical removal of
the primary tumour. The later, broader, more symmetrical risk
peaks indicate that some features of the corresponding
metastatic development may present stochastic traits. A
metastasis development model incorporating tumour dormancy
in specific micro-metastatic phases, stochastic transitions
between them and sudden acceleration of the metastatic
process by surgery can explain these risk dynamics.
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Introduction
The 1970s and 1980s witnessed a revolution in the con-
ventional approach to the treatment of primary breast can-
cer. Early in the 1970s, the favourable results of
postoperative systemic adjuvant therapy in women with
positive axillary lymph nodes [1,2] started an avalanche of
clinical trials that explored the role of several systemic treat-
ments in different subsets of patients. The beneficial results
were confirmed by a few overviews of randomised trials
[3,4], and reports from individual studies proved that the
benefit continued at 20 years of follow-up [5]. However, the
significant, albeit moderate, improvement of disease-free
survival and overall survival achieved by earlier adjuvant
therapy trials has improved only slightly during subsequent
years, despite a spate of new active drugs and the use of
higher drug doses [6]. The benefits of adjuvant therapyBreast Cancer Research    Vol 6 No 6    Demicheli et al.
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have therefore apparently reached a plateau, and it is
unlikely that further improvements will be obtained without
a more complete and accurate understanding of the biol-
ogy of the tumour–host system at the time of treatment.
Surgical resection of primary tumour removal may either
'cure' a significant fraction of patients, or it may even
change the 'natural' recurrence and death timing for some
others, by accelerating the metastatic development [7,8].
Some specific biological mechanisms supporting this
effect have been elucidated: in animals given surgery, a
growth-stimulating factor was found in serum [9] and a
switch of micro-metastatic foci to the angiogenic pheno-
type, due to withdrawal of an angiogenesis inhibitor from
the primary tumour, was demonstrated [10]. Despite these
provocative data, the residual tumour growth dynamics
underlying the beneficial results of all adjuvant systemic
treatments is virtually unknown in humans.
Careful inspection of the timing of tumour recurrence after
resection can be of considerable interest. The recurrence
risk pattern in a given follow-up span, a useful estimate of
which is the hazard function [11], provided information on
the biological behaviour of metastases. The hazard func-
tions for local-regional recurrences and distant metastases
for breast cancer patients undergoing mastectomy alone
[12] proved to be double-peaked, with an early peak at
about 18 months after surgery, a second peak at about 60
months, and a plateau-like tail extending out to 15 years,
the maximum period analysed. These findings were con-
firmed by a similar investigation on node-positive patients
receiving adjuvant CMF (cyclophosphamide, methotrexate,
fluorouracil) treatment [13], and a double-peaked hazard
function was also demonstrated for the timing of death after
primary tumour resection [14-16]. A reasonable hypothesis
to explain these findings is that the early peak of the hazard
function for recurrence is generated by the sudden accel-
eration of the metastatic process due to surgery. This
hypothesis was the cornerstone for a biological model for
the development of breast cancer metastasis, incorporat-
ing tumour dormancy in specific micro-metastatic phases
and stochastic transitions between them [17]. A computer
simulation of the model generated double-peaked relapse
histograms reasonably similar to clinical data [18].
The model and the results of its computer simulation sug-
gest that the first peak may result from the superimposition
of metastatic recurrences with different dynamics. Here we
report a detailed analysis of the first peak of the hazard rate
curve, that is, of the recurrence timing during the first 4
years, for patients undergoing mastectomy without any
adjuvant chemotherapy or radiotherapy. Our findings sug-
gest that metastatic growth dynamics after primary tumour
removal is markedly different depending on menopausal
status and, perhaps, axillary nodal involvement. These
results support the concept that surgery may have differen-
tial perturbing effects on tumour growth kinetics depending
on both tumour and host traits. These results strengthen
the leading lines of the proposed model for metastasis
development and may be relevant to adjuvant treatment
strategies.
Methods
All patients with mastectomy alone as primary treatment
who entered into three different clinical trials for operable
breast cancer were retrospectively evaluated for this analy-
sis. The trials were performed at the Milan Cancer Institute
between 1964 and 1980 to compare mastectomy with
other surgical or combined therapeutic approaches. Before
surgery, all patients underwent standard staging: complete
physical examination, X-ray study of chest, skull, spine and
pelvis, bilateral mammography, electrocardiogram, com-
plete haemogram and routine biochemical tests. The pri-
mary tumour was treated by radical or modified radical
mastectomy. No patient received postoperative radiother-
apy or chemotherapy. After surgery, follow-up was per-
formed as follows: physical examination, biochemical tests
and chest X-ray every 6–8 months during the first 3 years
and once a year thereafter; skeletal survey and mammogra-
phy once a year. In the presence of controversial clinical
findings, examinations were performed more often than
originally planned. Appropriate radiological, radioisotopic
and surgical investigations were performed whenever
recurrence was suspected or clinically evident. Particular
attention was paid to assessing the recurrence time by
carefully reviewing clinical, radiological and laboratory doc-
umentation. More detailed characteristics of the studied
series are reported in reference 12.
Treatment failure (recurrence) was defined as the first clin-
ically documented evidence of new disease manifesta-
tion(s) in either local-regional area(s) (namely chest wall,
axilla and/or ipsilateral supra-clavicular region) or distant
site(s) or any combination of these sites (classified as dis-
tant). Contra-lateral breast lesions may be either second
primaries (confounding factors in the present investigation)
or true metastases. Their annual incidence, together with
the absence of a link with clinical prognostic factors of the
primary breast cancer, suggest that most of them can be
considered as second primary breast cancers [12,19].
Contra-lateral tumours were therefore considered second
primaries.
Recurrence-free survival was considered as the time
elapsed from the date of surgery to the first documented
evidence of treatment failure; clinical evaluation without
recurrence, death without recurrence, and second primary
cancer (including contra-lateral breast cancer) were con-
sidered censored events.Available online http://breast-cancer-research.com/content/6/6/R689
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Our application involved dividing the time axis into discrete
intervals; the timing of the recurrence risk was studied by
estimating the recurrence hazard rate, namely the condi-
tional probability of manifesting recurrence in a time
interval, given that the patient is clinically free of any recur-
rence at the beginning of the interval. The discrete hazards
of recurrence and their standard deviations were calculated
by means of the life-table method over 4 years. Because
the event-specific rates display some instability arising from
random variation, a kernel-like smoothing procedure [20]
was adopted to aid the reader in visualising the underlying
pattern, and the smoothed curves were represented graph-
ically. Time intervals of 1, 2, 3, 6 and 12 months were used
in a preliminary smoothing analysis that showed that a 3-
month interval is a good compromise between smoothing
data and displaying structure. We therefore used the haz-
ard rate per 3-month interval.
Menopausal status, which was collected and recorded at
the time of primary tumour diagnosis, was defined as 'post-
menopausal' if 1 year had elapsed since the last menstrual
period. Cumulative survival curves were compared by two-
sided log-rank test.
Results
The main clinical characteristics of the 1173 analysed
patients, all undergoing regular follow-up examinations in
accordance with protocol requirements, are reported in
Table 1. A total of 368 patients suffered from treatment fail-
ure within 4 years of surgery: the tumour recurrence was
local-regional in 95 cases and distant in 273. A total of 749
patients were surviving and were at risk of recurrence at the
end of the fourth year. Patients were lost to follow-up at a
rate of 1.6% during the analysed years.
As reported and discussed elsewhere [12], the hazard rate
for recurrence of all patients during 10 years of follow-up
(Fig. 1a) displays a double-peaked pattern. In the present
study we focused on the first peak (Fig. 1b), which shows
an asymmetrical pattern with an early steep rise, reaching
the maximum recurrence risk at the end of the first year, fol-
lowed by a slight decrease lasting about 1.5 years and then
by a more distinct decline until the end of the fourth year.
This shape suggests that the recurrence risk curve may
result from the superimposition of differently timed peaks.
As a first step, the hazard rate pattern by type of recurrence
(local-regional versus distant) was studied and, because
their timing proved to be remarkably similar, in the further
analysis both recurrences were combined. Patients were
then allocated to different subsets according to tumour size
(T1 versus T2–T3) or to axillary nodal status (positive ver-
sus negative) or to menopausal status (pre-menopausal
versus post-menopausal). The resulting hazard rate curves
indicated that the recurrence risk pattern is definitely corre-
lated to menopausal status, with a double-peaked curve for
pre-menopausal patients (Fig. 2a) and a single-peaked
curve for post-menopausal women (Fig. 2b). Tumour size
did not show a noticeable influence on the recurrence risk
pattern, and this finding was confirmed by the analysis of
further subsets of patients (T1 and T2–T3 N-pre-menopau-
sal, T1 and T2–T3 N+ pre-menopausal, T1 and T2–T3 N-
post-menopausal, T1 and T2–T3 N+ post-menopausal), in
whom tumour size (as well as type of recurrence) failed to
change the hazard rate pattern (data not shown).
Pre-menopausal patients were allocated to subsets of
node-negative, node-positive, one to three nodes positive
and more than three nodes positive, and the hazard rates
were estimated (Fig. 3). The resulting curves show that for
node-positive patients, the recurrence risk has a quite
narrow early peak, with a very steep rise to a maximum at
about 8–10 months after mastectomy, and a second wider
increase peaking at about 28–30 months. The recurrence
pattern and the peak position do not change for patients
Table 1
Main patient characteristics
Parameter Value
Total number 1173
Median age, years (range) 52 (23–82)
Pre-menopausal 517
Tumour size
T1 222
T2 265
T3 30
Axillary nodes
N- 266
N+(1–3) 158
N+(>3) 93
Post-menopausal 656
Tumour size
T1 237
T2 363
T3 56
Axillary nodes
N- 332
N+(1–3) 184
N+(>3) 140Breast Cancer Research    Vol 6 No 6    Demicheli et al.
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with different axillary involvement, whereas the peak height
is positively correlated with the extent of nodal invasion.
A similar analysis was performed in post-menopausal
patients. All subsets of patients displayed a wide, nearly
symmetrical recurrence risk peak, with a maximum at 18–
24 months and a height similar to the corresponding esti-
mates of pre-menopausal patients (Fig. 4). Even for these
patients the extent of axillary node invasion was positively
correlated to the peak height.
The recurrence risk for node-negative patients displays an
initial regular increase reaching a maximum at about 18–24
months after surgery, with a mild decrease afterwards. No
multi-peaked pattern was evident or even suggested for
either pre-menopausal (Fig. 3a) or post-menopausal (Fig.
4a) women. However, it should be noted that of the 598
node-negative patients at risk, only 74 recurrences were
observed during the 4 years under investigation, 43 of
which occurred within 2 years. The reported results, mainly
those from the third and subsequent years, should there-
fore be very cautiously considered.
Figure 1
Hazard rate for breast cancer recurrence (local-regional plus distant)  after mastectomy alone as primary treatment in 1173 patients Hazard rate for breast cancer recurrence (local-regional plus distant) 
after mastectomy alone as primary treatment in 1173 patients. Calcu-
lated values (squares) with standard deviations (oblongs) and interpola-
tion curve covering 10 years of follow-up (a) and magnification of the 
first 4 years (b).
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Figure 2
Hazard rate for breast cancer recurrence (local-regional plus distant)  after mastectomy alone as primary treatment in 1173 patients: (a) pre- menopausal patients; (b) post-menopausal patients Hazard rate for breast cancer recurrence (local-regional plus distant) 
after mastectomy alone as primary treatment in 1173 patients: (a) pre-
menopausal patients; (b) post-menopausal patients. Calculated values 
(squares) with standard deviations (oblongs) and interpolation curve 
covering the first 4 years of follow-up.
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Discussion
First of all, it should be emphasised that findings resulting
from the different subsets of patients are notably coherent.
A remarkably stable two-peaked hazard function, with
increasing peak height associated with the increasing axil-
lary lymph node involvement, describes the risk of recur-
rence for pre-menopausal patients, whereas, quite
differently, post-menopausal women always display a sin-
gle peak. Moreover, each observed peak maintains the
same position on the time axis in all analysed subsets of
pre-menopausal and post-menopausal women. The occur-
rence of these peaks by chance, that is, resulting from ran-
dom fluctuations of the recurrence timing, should therefore
be considered very unlikely. Obviously, our findings must
be confirmed by similar analyses of other comparable
databases.
We add here some important details to the previously
reported investigation on the recurrence risk pattern of this
same series [12]. Indeed, we found that even though pre-
menopausal and post-menopausal patients display similar
long time results (10-year recurrence-free survival: 56%
versus 54%; not significant) and similar overall recurrence
pattern (early surge during the first 4 years, a second minor
increase at about 5 years and a tapering phase afterwards),
the early recurrence dynamics may be very different
between pre-menopausal and post-menopausal women.
A very early significant difference in the recurrence risk
between pre-menopausal and post-menopausal patients
had already been noted [21]. In the present analysis we
found that these differences cover all the first 4 years and
persist in all patient subsets. Summarising, the recurrence
risk for pre-menopausal patients displays an abrupt
increase at the third 3-month period; it quickly reaches its
prominent maximum level (about four times the level of the
previous 6 months) and is followed by a second fairly sym-
metrical and considerably broader peak appearing at about
18 months of follow-up, with its maximum at 28–30 months
after surgery. In comparison, the recurrence risk for post-
menopausal patients is nearly symmetrical and, after a
smooth increase, reaches its maximum level at about 18
months after primary tumour removal. These findings are
clear in node-positive patients, and the higher the nodal
involvement, the higher the amplitude of peaks. The limited
number of events prevents us from drawing any conclusion
for node-negative patients. Tumour size affects the recur-
rence risk value at a given time but does not affect the pat-
tern of the hazard rate distribution (that is, the occurrence
of peaks).
It is difficult not to be impressed by the particular shape of
the first recurrence peak of pre-menopausal node-positive
patients and by the difference between it and the others of
both menopausal subsets. It is also difficult, in the presence
Figure 3
Hazard rate for breast cancer recurrence (local-regional plus distant)  after mastectomy alone as primary treatment in pre-menopausal  patients: (a) node-negative versus node-positive; (b) node-positive  (one to three) lymph nodes; (c) node-positive (more than three) lymph  nodes Hazard rate for breast cancer recurrence (local-regional plus distant) 
after mastectomy alone as primary treatment in pre-menopausal 
patients: (a) node-negative versus node-positive; (b) node-positive 
(one to three) lymph nodes; (c) node-positive (more than three) lymph 
nodes. Calculated values (squares and diamonds) with standard devia-
tions (oblongs) and interpolation curve covering the first 4 years of fol-
low-up (N-, 34 events; N+(1–3), 61 events; N+(>3), 60 events).
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of a such an abrupt and prominent increase of the recur-
rence risk, to imagine something different from a triggering
event resulting in recurrence synchronisation.
As a first step, some possible non-biology-based explana-
tions of this finding should be considered. The peak could
be related to inadequate staging evaluation, because at the
time of the study no bone scan, liver ultrasound or com-
puted tomography scan staging was done. Patients with
undiscovered metastatic disease at diagnosis would
therefore have displayed recurrence at the initial post-treat-
ment screening, thus contributing to the first peak. How-
ever, it should be considered that, for newly diagnosed
otherwise asymptomatic operable patients, (1) very few
cases prove to be metastatic at standard staging today
(less than 5%) [22] and (2) bone scan ultrasound and com-
puted tomography scan surveys have a very low detection
rate (less than 1%) [23,24] and are not routinely recom-
mended in these patients [25]. Even chest X-ray was con-
sidered unnecessary at staging of asymptomatic operable
breast cancer, because of its very low diagnostic yield
(0.1%) [26]. Therefore, even if a few missed metastatic
patients at primary tumour diagnosis might not have been
excluded, they would have had little influence on the
observed first peak of recurrence risk involving, for pre-
menopausal node-positive patients, 22% of eligible
patients and 37% of recurrences within 10 years. Moreo-
ver, because up to 75% of breast cancer recurrences are
detected by the patient and reported to the physician within
a mean time of 1 month [27,28], we can reliably consider
the observed recurrence timing as widely independent of
the planned follow-up timing. Last but not least, post-men-
opausal patients, who underwent the same clinical man-
agement as pre-menopausal ones, did not display an early
peak. A significant role of screening and diagnostics can
therefore reasonably be ruled out and a biology-based
explanation should be investigated.
The first sharp peak, in our opinion, has a biological expla-
nation and may result from some triggering event changing
the unperturbed history of the disease. We suggest that
primary tumour surgical removal is probably this event,
selectively operating on some micro-metastases within sim-
ilar biological conditions. This triggering effect could be
modulated by the surgery extent [29]. However, in the
present investigation data about the different surgical
approaches (namely radical versus modified radical mas-
tectomy) were not considered suitable for such an analysis,
which would be more usefully performed for trials compar-
ing mastectomy with breast-conserving surgery. The likely
triggering effect of mastectomy is also supported by the
peak position, implying a rapid activation and growth within
8–10 months. This is in quite good agreement with esti-
mates of tumour growth after dormancy release (30 ± 8
weeks or less) obtained by very different methodology [30].
Figure 4
Hazard rate for breast cancer recurrence (local-regional plus distant)  after mastectomy alone as primary treatment in post-menopausal  patients: (a) node-negative versus node-positive; (b) node-positive  (one to three) lymph nodes; (c), node-positive (more than three) lymph  nodes Hazard rate for breast cancer recurrence (local-regional plus distant) 
after mastectomy alone as primary treatment in post-menopausal 
patients: (a) node-negative versus node-positive; (b) node-positive 
(one to three) lymph nodes; (c), node-positive (more than three) lymph 
nodes. Calculated values (squares and diamonds) with standard devia-
tions (oblongs) and interpolation curve covering the first 4 years of fol-
low-up (N-, 40 events; N+(1-3), 84 events; N+(>3), 88 events).
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Assuming tumour dormancy release and the estimate of 8–
10 months or less for tumour development from micro-
metastasis to clinical metastasis, the hazard function
should be considered as a description of the dormancy
escape kinetics. A symmetrical, bell-shaped peak in the
curve of hazard rate against time provides information
about both the mean value (the peak position) and the var-
iance (the peak width) of the timing of the constituent recur-
rences. The temporally stable position of the recurrence
peak therefore suggests a common cause for recurrence
development, a narrow peak indicates that the underlying
event is most probably deterministic in nature, and a con-
siderably wider peak suggests that some features of the
transition from dormancy to growth may also present sto-
chastic traits.
We recently proposed a model [17,18,31] in which breast
cancer metastasis development may include successive
steps: first, single cells (or nests containing a few cells),
where most of malignant cells are non-dividing; second,
non-angiogenic micro-metastases (and angiogenic ones in
the presence of anti-angiogenic factors) that cannot grow
more than the size of avascular foci; and third, vascularised
metastases that will reach the clinical level. This orderly
process is apparently perturbed by surgical removal of the
primary tumour, which can stimulate cells to proliferate and/
or remove angiogenic inhibition, thus resulting, for some
patients, in sudden acceleration of the metastatic process.
The proposed model both reasonably explains and takes
support from the findings of this study. The early sharp peak
of the recurrence risk for pre-menopausal patients can be
ascribed to a considerable switching of micro-metastatic
foci to the angiogenic phenotype via the withdrawal of
angiogenesis inhibitor(s) [10], and the sharpness of this
peak supports the deterministic character of the triggering
event. For post-menopausal patients, for whom the first
sharp peak is absent, this effect may be much more mod-
est. Other broader peaks may result from the induced pro-
liferation of single cells through one or more growth-
stimulating factors [9], resulting in successive avascular
micrometastases, followed by the 'spontaneous' switching
to the angiogenic phenotype, a process with stochastic
characteristics, in keeping with peak shapes.
As regards differences between pre-menopausal and post-
menopausal patients, it should be taken into account that
peculiar conditions relevant to breast cancer development,
in particular conditions acting on angiogenetic traits, may
be dependent on the host hormone milieu. Angiogenesis in
invasive breast carcinoma, as evaluated by micro-vessel
counts, is associated inversely with patient age, and higher
vascular intensity is observed in younger patients [32,33].
Vascular endothelial growth factor, the first member of a
family of glycoproteins with considerable stimulating activ-
ity for angiogenesis and lymphangiogenesis, waxes and
wanes in normal breast tissue within each menstrual cycle
[34]. Angiogenin, another potent angiogenic factor, dis-
plays a significant difference between serum levels drawn
in the proliferative and secretory phases of the menstrual
cycle [35]. Plasma levels of endostatin, a negative regulator
of angiogenesis, are significantly higher in post-menopau-
sal patients [36]. It is therefore reasonable to assume that
some conditions related to menopausal status may select
neoplastic cell populations with peculiar traits relative to
angiogenesis. A further factor may have a role: it has been
suggested that timing of surgery in the menstrual cycle
might modulate the tumour–host relationship and ultimately
the disease outcome [37]. This occurrence is restricted,
obviously, to pre-menopausal patients.
The findings of this investigation would be much more com-
plete if other prognostic and predictive factors could be
analysed. However, this database, like most databases of
patients undergoing surgery alone without any adjuvant
treatment, goes back to years when factors other than TNM
(tumor, nodes, metastases) staging and menopausal status
were poorly known or completely unknown.
Conclusions
Early metastatic growth dynamics shows a structured pat-
tern that is correlated to menopausal status. Indeed, during
the first 4 years, node-positive pre-menopausal patients
display a split of the hazard function surge into two peaks,
while post-menopausal patients always display a single
peak. The timing and shape of peaks suggest the occur-
rence of some triggering event, correlated with primary
tumour surgical removal, resulting in recurrence synchroni-
sation, which seems to be especially important for pre-men-
opausal node-positive patients. In addition, findings
support the hypothesis that some features of metastatic
development may present stochastic traits. A metastasis
development model incorporating tumour dormancy, sto-
chastic transitions between specific micro-metastatic
phases and sudden acceleration of the metastatic process
due to surgery may be considered appropriate and to fit
these findings well.
The different post-resection relapse dynamics between
pre-menopausal and post-menopausal patients may have
important implications for adjuvant systemic treatments.
For adjuvant chemotherapy the proposed picture makes it
easier to understand retrospectively why adjuvant chemo-
therapy was found to be most effective in pre-menopausal
patients, who during the first months after primary tumour
removal would display an enhancement of actively prolifer-
ating, and hence more chemo-sensitive, micro-metastases
[38]. Most importantly, the prominent role of angiogenesis
in the surgery-driven dormancy escape for pre-menopausalBreast Cancer Research    Vol 6 No 6    Demicheli et al.
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patients suggests that early (preoperative) antiangiogenic
treatment might favourably influence prognosis.
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